ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GSK Gsk Plc

1,638.00
2.00 (0.12%)
Last Updated: 15:26:02
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.00 0.12% 1,638.00 1,637.00 1,638.00 1,656.00 1,635.00 1,642.00 2,631,960 15:26:02
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.77 67.85B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,636p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £67.85 billion. Gsk has a price to earnings ratio (PE ratio) of 13.77.

Gsk Share Discussion Threads

Showing 18776 to 18799 of 33100 messages
Chat Pages: Latest  760  759  758  757  756  755  754  753  752  751  750  749  Older
DateSubjectAuthorDiscuss
08/1/2019
11:50
Market up 65 Gsk down and stuck around 15. Is there any share more dissapointing apart from Imperial. That buyout of an overpriced bio pharma with semi failed research, just dont get it...management seems hell bent on weighing down the share price At least the chairman and major shareholders bounced her into splitting altho time frame glacial, they must have sussed shareholders at end of their tether.
porsche1945
08/1/2019
09:58
Because it is important that she establishes herself in the role and demonstrates through achievements/results that there is a foundation to the level of enthusiasm that she exudes, to assure others (investors).


I am optimistic that the company is re-aligning and investing in the right direction, but I take a more outwardly cautious stance, choosing to avoid emotional peaks and troughs in business …. ;0)

tradermichael
08/1/2019
09:44
TM. If you knew her well then you would be qualified to urge caution concerning her enthusiasm, but if you don’t, then how is enthusiasm, of itself. worrying??
jadeticl3
08/1/2019
08:50
Emma's interviews contain a lot of rhetoric - politicalspeak - and its worrying to witness the amount of high enthusiasm she exudes
tradermichael
07/1/2019
20:16
GSK chief Walmsley not finished with business shakeup

In an interview with CNBC's Jim Cramer, GlaxoSmithKline (GSK +0.7%) CEO Emma Walmsley says there are "tremendous opportunities" to improve operating performance, adding that the company will get "radical" about reshaping its portfolio.



"More acquisitions given the delevered balance sheet?"

wbecki
07/1/2019
20:15
"GSK/Pfizer consumer merger – multiple arbitrage, synergies and focus"
Summary

GlaxoSmithKline and Pfizer are merging their consumer health businesses to form the largest OTC drug maker in the world.

The transaction is expected to create synergies resulting in nearly 30% earnings growth for the new company.

Financial engineering through recapitalized balance sheets and multiple arbitrage will unlock additional value for shareholders.

Both GlaxoSmithKline and Pfizer are coming out ahead. GlaxoSmithKline is effectively splitting into two more focused companies while Pfizer is selling a non-core asset at a premium in a tax-advantaged spin/merge.




Presumably deleveraging the balance sheet of the Pharma company, by ramping the indebtedness of the Consumer health biz demerged into this JV, along with all of its positive cashflow, means Pharma division remaining less able to smooth peaks & troughs of earnings vis the dividend?????

So far more dependent on securing the next drug blockbuster.

Share this posters sentiments myself.


WelshWB
Comments35 | + Follow
@Okapi Research
Thanks for the reply as a pharma business GSK is skating on thin ice it has a very reduced pipeline of drugs compared to companies like ROCHE, Pfizer, Astrazeneca, Merck and Lilly to name a few. Recently GSK agreed to purchase Tesaro to improve its pipeline but not sure how that will pan out. I think I'm going to look further on its pipeline and price on offer.

wbecki
07/1/2019
16:47
GSK adrs up in the US after the Crammer interview.
montyhedge
07/1/2019
16:44
Wow Crammer was so excited over GSK.
montyhedge
07/1/2019
16:37
Walsmley on CNBC with Crammer now, see is brilliant. These will be over 2000p in a couple of years.
montyhedge
07/1/2019
11:39
Eli Lilly to buy Loxo Oncology for $8 billion in huge bet on cancer genetics
philanderer
07/1/2019
11:01
GSK should buy Futura Medical (FUM) asap it has the best erectile dysfunction drug which is in Phase 3 with results expected in 2H 2019 ,the drug has $1+billion potential . The company is valued at ridiculous £14 million thats a lifetime opportunity .
ih_116147
07/1/2019
08:50
Thought their Buy target would be 1875p. Still 1700p not to bad.
montyhedge
04/1/2019
12:05
4th jan UBS buy tp 1700p
philanderer
04/1/2019
11:20
There's more life in our local cemetery than there is in this share price ;)
gbh2
04/1/2019
09:49
Thanks I need that
abdullla
04/1/2019
09:42
where have you been the last few weeks adul must filter again
billionairepaddy
04/1/2019
08:40
That's alright - GSK dividend pays out next Thursday - I'll buy some more while its cheap ….. ;0)
tradermichael
04/1/2019
08:35
General ftse sell off in process !
gbh2
04/1/2019
08:14
Will put pressures on GSK and Pfizer
abdullla
04/1/2019
08:11
Obviously bad news for pharmas here
abdullla
03/1/2019
23:56
US drug maker Bristol-Myers Squibb agrees to buy rival Celgene in £71bn deal
philanderer
03/1/2019
15:57
Forget FANGS buy pharmaceuticals.
montyhedge
03/1/2019
08:41
£1 = 1.25595 USD should keep the red dot above the red line ….. ;0)
tradermichael
03/1/2019
08:35
Daily Mail and Montyhedge share of 2019 GSK got to be a winner.
montyhedge
Chat Pages: Latest  760  759  758  757  756  755  754  753  752  751  750  749  Older

Your Recent History

Delayed Upgrade Clock